BACLOFEN Drug Interactions
Also known as: Baclofen (Intrathecal)
Baclofen (Intrathecal) is a medication delivered directly into the fluid surrounding your spinal cord to help manage severe muscle stiffness and spasms, known as spasticity. It works by relaxing your muscles, which can improve movement and reduce discomfort caused by conditions like spinal cord injury or multiple sclerosis. This treatment is typically used when other baclofen forms haven't been effective or caused too many side effects.BACLOFEN has 10 documented drug interactions in our database, including 0 contraindicated, 10 major, 0 moderate, and 0 minor interactions.
0
Contraindicated
10
Major
0
Moderate
0
Minor
Patients may experience profound sedation, respiratory depression, hypotension, and psychomotor impairment. In severe cases, this can progress to coma and death due to respiratory arrest. The risk is heightened in patients with pre-existing respiratory compromise or those receiving higher doses of either medication.
Mechanism
Both buprenorphine, an opioid partial agonist, and baclofen, a GABA-B receptor agonist, exert depressant effects on the central nervous system (CNS). When co-administered, their individual CNS depressant effects are additive, leading to an enhanced overall CNS depression. This synergistic action can compromise vital functions regulated by the brainstem, such as respiration.
Clinical Management
Avoid concomitant use of buprenorphine and baclofen if possible. If co-administration is unavoidable, initiate treatment with the lowest effective doses and titrate slowly, monitoring closely for signs of CNS and respiratory depression. Educate patients and caregivers about the risks and symptoms of CNS depression, and consider prescribing naloxone for at-risk patients.
Patients may experience profound sedation, respiratory depression, hypotension, and psychomotor impairment. This can manifest as unresponsiveness, shallow breathing, decreased oxygen saturation, and an increased risk of falls or accidents. The combination significantly increases the risk of life-threatening respiratory depression.
Mechanism
Fentanyl, an opioid agonist, primarily acts on mu-opioid receptors in the central nervous system (CNS) to produce analgesia and CNS depression. Baclofen, a GABA-B receptor agonist, also exerts its muscle relaxant effects and CNS depression through actions in the brain and spinal cord. The co-administration of these two agents leads to an additive depressant effect on the CNS.
Clinical Management
Avoid concomitant use of fentanyl and baclofen if possible. If co-administration is unavoidable, initiate both medications at the lowest effective doses and titrate slowly while closely monitoring for signs of CNS and respiratory depression. Educate patients and caregivers on the symptoms of respiratory depression and excessive sedation, and consider prescribing naloxone if appropriate for opioid overdose reversal.
This interaction can manifest as profound sedation, respiratory depression, hypotension, and psychomotor impairment. Patients may experience dizziness, confusion, decreased level of consciousness, and impaired coordination, increasing the risk of falls and accidents.
Mechanism
Oxycodone, an opioid analgesic, exerts its effects primarily through mu-opioid receptor agonism, leading to central nervous system (CNS) depression. Baclofen, a skeletal muscle relaxant, acts as a GABA-B receptor agonist, also causing CNS depression. The co-administration of these agents results in an additive depressant effect on the CNS.
Clinical Management
Concomitant use should generally be avoided or approached with extreme caution, especially in opioid-naive patients or those with respiratory compromise. If co-administration is necessary, start with lower doses of both medications, monitor patients closely for signs of respiratory depression and excessive sedation, and educate them on the risks.
Patients may experience profound sedation, respiratory depression, hypotension, and impaired psychomotor function. This can manifest as excessive drowsiness, confusion, dizziness, and difficulty breathing, potentially leading to falls, aspiration, and life-threatening respiratory arrest. The combination significantly increases the risk of overdose symptoms.
Mechanism
Morphine, an opioid analgesic, exerts its effects primarily through mu-opioid receptor agonism, leading to central nervous system (CNS) depression. Baclofen, a gamma-aminobutyric acid (GABA)-B receptor agonist, also causes CNS depression by hyperpolarizing neurons and reducing neurotransmitter release. The co-administration of these agents results in an additive depressant effect on the CNS.
Clinical Management
Concomitant use should be avoided if possible. If co-administration is necessary, initiate both medications at the lowest effective doses and titrate cautiously, closely monitoring for signs of CNS and respiratory depression. Educate patients and caregivers on the symptoms of excessive sedation and respiratory depression, advising them to seek immediate medical attention if these occur. Consider prescribing naloxone for at-risk patients.
Patients may experience profound sedation, respiratory depression, hypotension, and impaired psychomotor function. This can lead to an increased risk of falls, accidental injury, and potentially life-threatening respiratory compromise. Symptoms may include extreme drowsiness, confusion, dizziness, shallow breathing, and unresponsiveness.
Mechanism
Tramadol, an opioid analgesic, primarily exerts its effects through mu-opioid receptor agonism and inhibition of norepinephrine and serotonin reuptake. Baclofen, a skeletal muscle relaxant, acts as a GABA-B receptor agonist in the spinal cord. The concomitant use of these agents results in additive central nervous system (CNS) depression.
Clinical Management
Avoid concomitant use if possible. If co-administration is necessary, initiate both medications at the lowest effective doses and titrate slowly, closely monitoring for signs of CNS and respiratory depression. Educate patients about the risks and advise them to avoid driving or operating heavy machinery. Consider alternative therapies if the risk outweighs the benefits.
Patients may experience severe CNS depression, including profound sedation, somnolence, and confusion. There is an increased risk of life-threatening respiratory depression, characterized by decreased respiratory rate and depth, potentially leading to hypoxia and hypercapnia. Additionally, impaired psychomotor function, dizziness, and ataxia are common, increasing the risk of falls and accidents.
Mechanism
Codeine sulfate, an opioid analgesic, and baclofen, a central nervous system (CNS) depressant and muscle relaxant, both act on the CNS to produce sedative effects. Their co-administration results in an additive depressant effect on the CNS, leading to enhanced inhibition of neuronal activity. This synergistic action can significantly impair respiratory drive and neurological function.
Clinical Management
Concomitant use should be avoided if possible. If co-administration is unavoidable, initiate both medications at the lowest effective doses and titrate slowly while closely monitoring for signs of CNS and respiratory depression. Educate patients and caregivers about the risks and symptoms of CNS depression and respiratory compromise, advising them to seek immediate medical attention if these occur. Consider alternative therapies if the risks outweigh the benefits.
The primary clinical effects include increased risk of severe respiratory depression, profound sedation, coma, and even death. Patients may experience dizziness, confusion, impaired psychomotor function, and hypotension. These effects are particularly dangerous in opioid-naive individuals or those with pre-existing respiratory compromise.
Mechanism
Methadone is a mu-opioid receptor agonist that causes central nervous system (CNS) depression, including respiratory depression and sedation. Baclofen is a gamma-aminobutyric acid (GABA)-B receptor agonist that also produces CNS depression, muscle relaxation, and sedation. The co-administration of these two agents results in an additive depressant effect on the CNS.
Clinical Management
Avoid concomitant use of methadone and baclofen if possible. If co-administration is necessary, initiate both medications at the lowest effective doses and titrate slowly while closely monitoring for signs of respiratory depression and sedation. Educate patients and caregivers about the risks and symptoms of CNS depression and respiratory compromise, and ensure naloxone is available if appropriate.
The concurrent use of hydromorphone and baclofen significantly increases the risk of severe CNS depression, including profound sedation, respiratory depression, coma, and even death. Patients may experience impaired psychomotor function, dizziness, confusion, and hypotension.
Mechanism
Hydromorphone, an opioid agonist, produces central nervous system (CNS) depression by binding to mu-opioid receptors. Baclofen, a GABA-B receptor agonist, also causes CNS depression by inhibiting neuronal activity in the spinal cord and brain. The co-administration of these agents results in an additive depressant effect on the CNS.
Clinical Management
Avoid concomitant use of hydromorphone and baclofen if possible. If co-administration is unavoidable, initiate treatment with the lowest effective doses of both drugs and titrate slowly while closely monitoring for signs of respiratory depression and sedation. Educate patients and caregivers on the symptoms of CNS depression and respiratory compromise.
Patients may experience increased sedation, dizziness, confusion, and psychomotor impairment. The most significant risk is profound respiratory depression, which can be life-threatening. Other effects include hypotension and coma.
Mechanism
Oxymorphone is an opioid analgesic that acts as a mu-opioid receptor agonist, causing central nervous system (CNS) depression. Baclofen is a gamma-aminobutyric acid (GABA) analogue that acts as a GABA-B receptor agonist, also producing CNS depressant effects. The co-administration of these two agents results in an additive depressant effect on the CNS.
Clinical Management
Avoid concomitant use if possible. If co-administration is necessary, initiate both drugs at the lowest effective doses and titrate slowly. Closely monitor patients for signs of respiratory depression, sedation, and altered mental status, especially during initiation or dose adjustments. Educate patients about the risks and advise against operating machinery or driving.
Patients may experience profound sedation, respiratory depression, hypotension, and impaired psychomotor function. This can lead to increased risk of falls, accidental injury, and potentially life-threatening respiratory compromise. Other effects include dizziness, confusion, and decreased level of consciousness.
Mechanism
Tapentadol is an opioid analgesic with mu-opioid receptor agonist activity and norepinephrine reuptake inhibition, both contributing to central nervous system (CNS) effects. Baclofen is a gamma-aminobutyric acid (GABA) analogue that acts as a GABA-B receptor agonist, primarily causing CNS depression and skeletal muscle relaxation. The co-administration of these agents results in additive CNS depressant effects.
Clinical Management
Concomitant use should generally be avoided due to the high risk of additive CNS and respiratory depression. If co-administration is unavoidable, initiate both medications at the lowest effective doses and titrate cautiously while closely monitoring for signs of respiratory depression and excessive sedation. Educate patients and caregivers about the risks and symptoms of CNS depression and advise against operating heavy machinery or driving.
For complete prescribing information:
View full BACLOFEN monograph →Medical Disclaimer
The information on RxGuide is intended for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician, pharmacist, or other qualified health provider with any questions you may have regarding a medical condition or medication. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.